OKYO Pharma: Chairman's associate buys 50,000 shares
Ticker: OKYO · Form: 6-K · Filed: Aug 23, 2024 · CIK: 1849296
Sentiment: neutral
Topics: insider-transaction, share-purchase
TL;DR
OKYO Pharma exec chairman's associate bought 50K shares.
AI Summary
On August 23, 2024, OKYO Pharma Ltd announced that Panetta Partners Limited, an entity associated with Executive Chairman Gabriele Cerrone, purchased 50,000 ordinary shares of the company. The filing does not specify the price or total value of this transaction.
Why It Matters
This purchase by an entity linked to the Executive Chairman could signal confidence in the company's future prospects.
Risk Assessment
Risk Level: low — The filing reports a share purchase by an insider-related entity, which is a common disclosure and does not inherently indicate significant new risks.
Key Numbers
- 50,000 — Ordinary Shares Purchased (Acquired by Panetta Partners Limited, an entity associated with the Executive Chairman.)
Key Players & Entities
- OKYO Pharma LTD (company) — Company making the announcement
- Panetta Partners Limited (company) — Entity that purchased shares
- Gabriele Cerrone (person) — Executive Chairman with beneficial interest in Panetta Partners Limited
- 50,000 (dollar_amount) — Number of ordinary shares purchased
FAQ
What was the date of the share purchase notification?
The notification was issued on August 23, 2024.
Who is Gabriele Cerrone?
Gabriele Cerrone is the Executive Chairman of OKYO Pharma LTD and has a beneficial interest in Panetta Partners Limited.
What entity purchased the shares?
Panetta Partners Limited purchased the shares.
How many shares were purchased?
50,000 ordinary shares were purchased.
What is the principal executive office address of OKYO Pharma LTD?
The principal executive office is located at 9th Floor, 107 Cheapside, London EC2V 6DN.
Filing Stats: 375 words · 2 min read · ~1 pages · Grade level 13.3 · Accepted 2024-08-23 07:00:07
Key Financial Figures
- $1.05 — dinary shares on NASDAQ at a price of US$1.05 per share. This brings the total shareh
Filing Documents
- form6-k.htm (6-K) — 21KB
- ex99-1.htm (EX-99.1) — 6KB
- ex99-1_001.jpg (GRAPHIC) — 37KB
- 0001493152-24-033638.txt ( ) — 79KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. OKYO Pharma LTD Date: August 23, 2024 By: /s/ Keeren Shah Name: Keeren Shah Title: Chief Financial Officer 3 EXHIBIT INDEX Exhibit No. Description 99.1 News Announcement, dated August 23, 2024 4